Disease-A-Month RSS feed: Current Issue. Designed for primary care physicians, each issue of Disease-a-Month presents an in-depth review of a single topic. In this way, the publication can cover all aspects of the topic-pathophysiology, clinical features of the disease or condition, diagnostic techniques, therapeutic approaches, and prognosis.http://www.diseaseamonth.com/?rss=yesElsevier Inc.en © 2010 Published by Elsevier Inc. All rights reserved. Disease-A-Month0011-5029563March 2010 © 2010 Published by Elsevier Inc. All rights reserved. healthpermissions@elsevier.comhttp://www.diseaseamonth.com/article/PIIS0011502910000131/abstract?rss=yesEditorial Board10.1016/S0011-5029(10)00013-1Disease-A-Month 56, 3 (2010)2010-03-01Disease-A-Month2010-03-01563S0011-5029(10)X0003-7IFCIFChttp://www.diseaseamonth.com/article/PIIS0011502910000143/abstract?rss=yesTitle Page10.1016/S0011-5029(10)00014-3Disease-A-Month 56, 3 (2010)2010-03-01Disease-A-Month2010-03-01563S0011-5029(10)X0003-7101101http://www.diseaseamonth.com/article/PIIS0011502910000155/abstract?rss=yesInformation for Readers10.1016/S0011-5029(10)00015-5Disease-A-Month 56, 3 (2010)2010-03-01Disease-A-Month2010-03-01563S0011-5029(10)X0003-7102102http://www.diseaseamonth.com/article/PIIS0011502910000167/abstract?rss=yesTable of Contents10.1016/S0011-5029(10)00016-7Disease-A-Month 56, 3 (2010)2010-03-01Disease-A-Month2010-03-01563S0011-5029(10)X0003-7103104http://www.diseaseamonth.com/article/PIIS0011502909001527/abstract?rss=yesThe American Journal of Therapeutics (AJT) was founded in 1994, 15 years ago, to be a source of information on medical therapeutics and the place of therapies in the medical armamentarium. While some journals emphasize clinical pharmacology, drug metabolism, or pharmacogenetics, AJT aims to cover the very diverse field of therapeutics. One aspect of therapeutics that this journal aims to cover is current approaches to medical therapeutics in different specialized fields. Jerrold B. Leikin, MD, a long-time contributor and member of the Editorial Board of AJT, as well as Editor-In-Chief of the Disease-a-Month, wanted to bring together some of the most informative therapeutic reviews from the AJT that covered therapeutic approaches across a number of areas.IntroductionJohn Somberg10.1016/j.disamonth.2009.12.004Disease-A-Month 56, 3 (2010)2010-03-01Disease-A-Month2010-03-01563S0011-5029(10)X0003-7105105http://www.diseaseamonth.com/article/PIIS0011502909001552/abstract?rss=yesAlzheimer's disease is the most prevalent and common form of cognitive impairment, ie, dementia, in the elderly followed in second place by vascular dementia due to the microangiopathy associated with poorly-controlled hypertension. Besides blood pressure elevation, advancing age is the strongest risk factor for dementia. Deterioration of intellectual function and cognitive skills that leads to the elderly patient becoming more and more dependent in his, her, activities of daily living, ie, bathing, dressing, feeding self, locomotion, and personal hygiene. It has been known and demonstrated for many years that lowering of blood pressure from a previous hypertensive point can result in stroke prevention yet lowering of blood pressure does not prevent the microangiopathy that leads to white matter demyelinization which when combined with the clinical cognitive deterioration is compatible with a diagnosis of vascular dementia. It is known from many large studies, ie, SHEP, SCOPE, and HOPE, that lowering of blood pressure gradually will not and should not worsen the cognitive impairment. However, if the pressure is uncontrolled a stroke which might consequently occur would further worsen their cognitive derangement. So an attempt at slow reduction of blood pressure since cerebral autoregulation is slower as age increases is in the patient's best interest. It is also important to stress that control of blood glucose can also be seen as an attempt to prevent vascular dementia from uncontrolled hyperglycemia. Vascular dementia is not considered one of the reversible causes of dementia. Reversible causes of cognitive impairment are over medication with centrally acting drugs such as sedatives, hypnotics, antidepressants, and antipsychotics, electrolyte imbalance such as hyponatremia, azotemia, chronic liver disease, and poor controlled chronic congestive heart failure. Criteria for the clinical diagnosis of vascular dementia include cognitive decline in regards to preceding functionally higher level characterized by alterations in memory and in two or more superior cortical functions that include orientation, attention, verbal linguistic capacities, visual spacial skills, calculation, executive functioning, motor control, abstraction and judgment. Patients with disturbances of consciousness, delirium (acute confusional states), psychosis, serious aphasia, or sensory-motor alterations that preclude proper execution of neuro-psychological testing are also considered to have probably vascular dementia. Furthermore, these are ten of the other essential cerebral or systematic pathologies present that would be able to produce a dementia syndrome.Hypertension and Cognitive Function in the ElderlyAntonio Cherubini, David T. Lowenthal, Esther Paran, Patrizia Mecocci, Leonard S. Williams, Umberto Senin10.1016/j.disamonth.2009.12.007Disease-A-Month 56, 3 (2010)2010-03-01Disease-A-Month2010-03-01563S0011-5029(10)X0003-7106147http://www.diseaseamonth.com/article/PIIS0011502909001576/abstract?rss=yesManagement of type 1 and type 2 diabetes is continually evolving, and among these evolving therapies is administration of insulin in its various forms. The insulin regimen needs to be tailored to each individual, not only to maximize compliance and glycemic control but also to minimize hypoglycemia and weight gain.Optimizing Insulin Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus: Optimal Dosing and Timing in the Outpatient SettingAllison J. Hahr, Mark E. Molitch10.1016/j.disamonth.2009.12.009Disease-A-Month 56, 3 (2010)2010-03-01Disease-A-Month2010-03-01563S0011-5029(10)X0003-7148162http://www.diseaseamonth.com/article/PIIS001150290900159X/abstract?rss=yesCytochrome P (CYP) 450 is a superfamily of hemoproteins that play an important role in the metabolism of steroid hormones, fatty acids, and many medications. Many agents used for management of cardiovascular diseases are substrates, inhibitors, or inducers of CYP450 enzymes. When two agents that are substrates, inhibitors, or inducers of CYP450 are administered together, drug interactions with significant clinical consequences may occur. This review discusses CYP450-mediated cardiovascular drug interactions as well as noncardiovascular drug interactions that produced significant cardiovascular side effects. The principles in predicting drug interactions are also discussed.Updates on Cytochrome P450-Mediated Cardiovascular Drug InteractionsJudy W.M. Cheng, William H. Frishman, Wilbert S. Aronow10.1016/j.disamonth.2009.12.011Disease-A-Month 56, 3 (2010)2010-03-01Disease-A-Month2010-03-01563S0011-5029(10)X0003-7163179